mProX™ Human TNFRSF8 Stable Cell Line

Product Information

Target Family

Oncology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;SU-DHL-1

Target Classification

Oncology Cell Lines

Target Research Area

Immunology Research

Related Diseases

Peripheral T-Cell Lymphoma; Mycosis Fungoides

Gene ID

Human:943

UniProt ID

Human:P28908

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF8, also known as CD30, has various applications in different fields. In the context of Alzheimer's disease (AD) and mild cognitive impairment (MCI), TNFRSF8 is studied as a potential biomarker for early detection. Urinary cytokine concentrations, including TNFRSF8, IL6ST, and IL-19, are analyzed to identify associations with AD and MCI development. Diagnostic models using these cytokines show promising performance in distinguishing AD from cognitively normal individuals. In-silico analysis enhances understanding of molecular mechanisms related to AD. TNFRSF8 is also explored in the context of cancer diagnosis and treatment. It is considered a tumor marker and is found on the surface of specific cells, including immune cells and cancer cells. CD30-targeted therapies are being investigated for CD30-positive lymphomas and autoimmune disorders. Additionally, TNFRSF8 is studied in triple-negative breast cancer (TNBC) to establish a cytokine-related gene signature for distinguishing and predicting prognosis. The signature includes TNFRSF8 along with other genes. Furthermore, TNFRSF8's role in adult T-cell leukemia/lymphoma (ATL) progression is examined. CD30 overexpression is observed in ATL cases caused by human T-cell leukemia virus type 1 (HTLV-1) infection, and its functions during disease progression are explored. Lastly, in the context of Mycobacterium tuberculosis (Mtb) infection, CD30 co-stimulation is found to drive the differentiation of protective T cells. CD30 expression on CD4 T cells is required for survival and protection against Mtb infection.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human TNFRSF8 Stable Cell Line (S01YF-1023-PY241). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Skyler Jones (Verified Customer)

What is the role of TNFRSF8 in cancer? Oct 19 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF8, also known as CD30, is involved in the modulation of T-cell proliferation and has been linked to various cancers, including non-keratinizing squamous cell carcinoma and myeloma . Oct 19 2020

chat Morgan Garcia (Verified Customer)

How does TNFRSF8 interact with other genes in disease progression? Feb 10 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

TNFRSF8 interacts with other genes in the immune system, influencing disease progression and response to treatments, as seen in conditions like multiple myeloma and oral lichen planus. Feb 10 2021

Published Data

Fig.1 A substantial reduction in cell growth was observed upon the utilization of specific siRNA constructs to silence TNFRSF8.

Ref: Atsaves, Vassilis, et al. "The oncogenic JUNB/CD 30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma." British journal of haematology 167.4 (2014): 514-523.

Pubmed: 25145835

DOI: 10.1111/bjh.13079

Research Highlights

Saiyed, Nazia. et al. "Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study." Journal of Alzheimer's disease reports, 2023.
Alzheimer's disease (AD) is a prevalent form of dementia, responsible for 80% of all cases. Mild cognitive impairment (MCI) lies in the middle of normal aging and AD. Detecting AD at an early stage is imperative, as the brain sustains irreversible harm before symptoms materialize. Œ≤-amyloid and tau protein are established as potential biomarkers for AD. Nonetheless, the current methods for biomarker identification are costly and invasive. The development of non-invasive and cost-effective techniques is necessary for efficient AD detection.
Saiyed, Nazia. et al. "Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study." Journal of Alzheimer's disease reports, 2023.
Pubmed: 37483327 DOI: 10.3233/ADR-220081

Vasile Dumitru, Adrian. et al. "The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment." Cells, 2023.
CD30, also referred to as TNFRSF8, is a heavily glycosylated protein receptor that serves as a tumor marker on specific cells in the body including immune and cancer cells. This review discusses the significance of CD30 in various diseases, such as Hodgkin lymphoma where it is expressed on Hodgkin and Reed-Sternberg cells, embryonal carcinoma, anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. Additionally, CD30 has shown potential as a treatment target for CD30-positive lymphomas and ongoing research is exploring its use in autoimmune disorders. The authors aim to examine CD30's role as a tumor marker and its potential as a target for cytostatic treatment.
Vasile Dumitru, Adrian. et al. "The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment." Cells, 2023.
Pubmed: 37443818 DOI: 10.3390/cells12131783